Regeneron Pharmaceuticals, Inc. (LON:0R2M)
London flag London · Delayed Price · Currency is GBP · Price in USD
546.04
-2.27 (-0.41%)
At close: Aug 1, 2025

Regeneron Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2020
Cash & Equivalents
1,9962,4882,7303,1062,8862,194
Upgrade
Short-Term Investments
5,4746,5248,1154,6362,8091,393
Upgrade
Cash & Short-Term Investments
7,4709,01310,8457,7425,6953,587
Upgrade
Cash Growth
-23.85%-16.90%40.07%35.96%58.76%11.59%
Upgrade
Accounts Receivable
5,3065,8445,2995,0235,0593,112
Upgrade
Other Receivables
304367.8368.5305.6977.51,003
Upgrade
Receivables
5,6106,2125,6675,3296,0374,115
Upgrade
Inventory
3,2063,0872,5812,4021,9511,917
Upgrade
Prepaid Expenses
554.5348.4386.6411.2332.4160.8
Upgrade
Restricted Cash
19.80.8----
Upgrade
Total Current Assets
16,86018,66119,47915,88414,0159,779
Upgrade
Property, Plant & Equipment
4,8414,8174,2243,8343,4823,222
Upgrade
Long-Term Investments
10,4679,0605,4716,6406,8783,195
Upgrade
Other Intangible Assets
1,3521,1491,039915.56.7-
Upgrade
Long-Term Deferred Tax Assets
3,5723,3142,5751,724876.9858.9
Upgrade
Other Long-Term Assets
1,128758.8291.8216.9176.1108.9
Upgrade
Total Assets
38,21937,75933,08029,21525,43517,163
Upgrade
Accounts Payable
723.9789.5606.6589.2564475.5
Upgrade
Accrued Expenses
2,4612,4972,3392,0541,5931,609
Upgrade
Current Portion of Leases
-30.31912.4719.7-
Upgrade
Current Income Taxes Payable
----326.319.5
Upgrade
Current Unearned Revenue
481.9627.7458.9485.3442577.7
Upgrade
Other Current Liabilities
----287.416.1
Upgrade
Total Current Liabilities
3,6673,9443,4233,1413,9332,697
Upgrade
Long-Term Debt
1,9851,9841,9831,9811,9801,979
Upgrade
Long-Term Leases
720924.1788.7775.8-717.2
Upgrade
Long-Term Unearned Revenue
206.3185.7126.769.873.357.8
Upgrade
Other Long-Term Liabilities
1,7021,367785.4582.2680.2687.1
Upgrade
Total Liabilities
8,2808,4067,1076,5516,6666,138
Upgrade
Common Stock
0.10.10.10.10.10.1
Upgrade
Additional Paid-In Capital
13,49112,85611,3549,9498,0886,716
Upgrade
Retained Earnings
33,68031,67327,26023,30718,96810,893
Upgrade
Treasury Stock
-17,285-15,167-12,560-10,353-8,261-6,613
Upgrade
Comprehensive Income & Other
52.5-7.9-80.9-238.8-26.229.3
Upgrade
Shareholders' Equity
29,93929,35425,97322,66418,76911,025
Upgrade
Total Liabilities & Equity
38,21937,75933,08029,21525,43517,163
Upgrade
Total Debt
2,7052,9392,7912,7702,7002,696
Upgrade
Net Cash (Debt)
14,82314,97413,45111,5659,8334,027
Upgrade
Net Cash Growth
-0.03%11.32%16.31%17.61%144.18%-30.05%
Upgrade
Net Cash Per Share
131.87130.09118.30101.8987.6434.99
Upgrade
Filing Date Shares Outstanding
103.69107.02107.46106.73106.44104.14
Upgrade
Total Common Shares Outstanding
104.12107.3107.12107106.57103.96
Upgrade
Working Capital
13,19314,71716,05612,74310,0827,082
Upgrade
Book Value Per Share
287.55273.57242.47211.81176.11106.05
Upgrade
Tangible Book Value
28,58728,20524,93521,74918,76211,025
Upgrade
Tangible Book Value Per Share
274.57262.86232.78203.26176.05106.05
Upgrade
Land
-288.2283.1264.5248241.2
Upgrade
Buildings
-2,5732,4232,2702,0891,891
Upgrade
Machinery
-2,1491,9401,8031,6621,395
Upgrade
Construction In Progress
-1,7221,345980.5767.7724.5
Upgrade
Leasehold Improvements
-154.5133.9114.3113.9100.5
Upgrade
Updated Feb 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.